| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Sep, 2023 | Jun, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -550 | -700 | 490 | -220 | -360 |
| Net Income Growth | +21.43% | -242.86% | +322.73% | +38.89% | +60.87% |
Xtl Biopharma ADR (XTLB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company developing drugs against hepatitis.
Fiscal Year End Date: 12/31